| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b01dcd61775e996fac631d4b10c4e87f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97ac5ac507accb4f1966d47f94d0a3a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59ec37318623e42970ac9b8cc9e49559 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y106-02004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y114-14001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
| filingDate |
2020-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6a52a08917469ad9e4f12d6297a17d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3dd1f1ace4419d9ee7a27e15b91c1f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e86d6e73197253c9bfb1edbb976e9543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2786e711d3a8614d0c241e68e0cb4bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b230541f46953b9f3be4679fba945579 |
| publicationDate |
2022-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022409668-A1 |
| titleOfInvention |
Genetically modified human stem cell expressing a mutant human cytochrome p450 2b6 protein and use thereof in the treatment of cancer |
| abstract |
The present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into one of the genomic safe harbors of said human stem cell. The invention also relates to the use of said cell for the treatment of cancer and/or cancer recurrences and/or associated metastases, particularly the solid tumours, and in particular the hepatocellular carcinomas and/or associated metastases. |
| priorityDate |
2019-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |